Monthly Archives: October 2016

http://www.lslog.com/rooting-for-pharmas-deal-volume-to-reach-2015s-heights-dont-hold-your-breath-report-says/Rooting for pharma's deal volume to reach 2015's heights? Don't hold your breath, report says

Rooting for pharma's deal volume to reach 2015's heights? Don't hold your breath, report says

Rooting for pharma’s deal volume to reach 2015’s heights? Don’t hold your breath, report says Rooting for pharma’s deal volume to reach 2015’s heights? Don’t hold your breath, report says […]

http://www.lslog.com/bms-to-overhaul-rd-operations-and-manufacturing-as-it-trots-out-street-beating-q3/BMS to overhaul R&D, operations and manufacturing as it trots out Street-beating Q3

BMS to overhaul R&D, operations and manufacturing as it trots out Street-beating Q3

BMS to overhaul R&D, operations and manufacturing as it trots out Street-beating Q3 BMS to overhaul R&D, operations and manufacturing as it trots out Street-beating Q3 esagonowsky Thu, 10/27/2016 – […]

http://www.lslog.com/gsk-drops-a-pair-of-late-stage-candidates-in-copd-hiv/GSK drops a pair of late-stage candidates in COPD, HIV

GSK drops a pair of late-stage candidates in COPD, HIV

GSK drops a pair of late-stage candidates in COPD, HIV GSK drops a pair of late-stage candidates in COPD, HIV slawrence Wed, 10/26/2016 – 15:35 Source: FierceMedicalDevices News GSK […]

http://www.lslog.com/biogen-aims-for-neuro-transformative-era-but-drops-late-stage-ms-candidate/Biogen aims for neuro 'transformative era' but drops late-stage MS candidate

Biogen aims for neuro 'transformative era' but drops late-stage MS candidate

Biogen aims for neuro ‘transformative era’ but drops late-stage MS candidate Biogen aims for neuro ‘transformative era’ but drops late-stage MS candidate slawrence Wed, 10/26/2016 – 14:09 Source: FierceMedicalDevices […]

http://www.lslog.com/is-ceo-vigodman-to-blame-for-tevas-recent-turmoil-some-investors-think-so/Is CEO Vigodman to blame for Teva's recent turmoil? Some investors think so

Is CEO Vigodman to blame for Teva's recent turmoil? Some investors think so

Is CEO Vigodman to blame for Teva’s recent turmoil? Some investors think so Is CEO Vigodman to blame for Teva’s recent turmoil? Some investors think so chelfand Wed, 10/26/2016 – […]

http://www.lslog.com/gsk-defies-detractors-again-as-new-products-amp-up-q3-sales-beat/GSK defies detractors again as new products amp up Q3 sales beat

GSK defies detractors again as new products amp up Q3 sales beat

GSK defies detractors again as new products amp up Q3 sales beat GSK defies detractors again as new products amp up Q3 sales beat chelfand Wed, 10/26/2016 – 11:43 […]

http://www.lslog.com/cf-fighter-orkambi-picks-up-steam-as-vertex-forges-ahead-with-vx-661-combos/CF fighter Orkambi picks up steam as Vertex forges ahead with VX-661 combos

CF fighter Orkambi picks up steam as Vertex forges ahead with VX-661 combos

CF fighter Orkambi picks up steam as Vertex forges ahead with VX-661 combos CF fighter Orkambi picks up steam as Vertex forges ahead with VX-661 combos esagonowsky Tue, 10/25/2016 – […]

http://www.lslog.com/gsk-partners-with-startup-to-develop-antibiotic-alternative/GSK partners with startup to develop antibiotic alternative

GSK partners with startup to develop antibiotic alternative

GSK partners with startup to develop antibiotic alternative GSK partners with startup to develop antibiotic alternative slawrence Tue, 10/25/2016 – 16:12 Source: FierceMedicalDevices News GSK partners with startup to […]

http://www.lslog.com/merck-talks-io-combo-strategy-as-keytruda-nabs-first-line-nsclc-approval/Merck talks I/O combo strategy as Keytruda nabs first-line NSCLC approval

Merck talks I/O combo strategy as Keytruda nabs first-line NSCLC approval

Merck talks I/O combo strategy as Keytruda nabs first-line NSCLC approval Merck talks I/O combo strategy as Keytruda nabs first-line NSCLC approval slawrence Tue, 10/25/2016 – 14:51 Source: FierceMedicalDevices […]

http://www.lslog.com/lilly-falls-short-in-q3-as-rebates-discounts-thump-its-diabetes-mainstay-humalog/Lilly falls short in Q3 as rebates, discounts thump its diabetes mainstay Humalog

Lilly falls short in Q3 as rebates, discounts thump its diabetes mainstay Humalog

Lilly falls short in Q3 as rebates, discounts thump its diabetes mainstay Humalog Lilly falls short in Q3 as rebates, discounts thump its diabetes mainstay Humalog arlene.weintraub Tue, 10/25/2016 – […]